DEFA14A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2011

MEDCO HEALTH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-31312	22-3461740
(State or other Jurisdiction of	(Commission File Number)	(IRS Employer Identification No.)
Incorporation)

100 Parsons Pond Drive, Franklin Lakes, NJ	07417
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: 201-269-3400

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

þ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

Beginning July 29, 2011, Medco Health Solutions, Inc. distributed the following materials, which are attached hereto and incorporated herein by reference:

• BetterRxCare.com — Home Page

• BetterRxCare.com — Clients Page

• BetterRxCare.com — Pharmacies Page

• BetterRxCare.com — Consumers Page

• BetterRxCare.com — Investor Presentation

• BetterRxCare.com — Factsheet

• BetterRxCare.com — Merger Photos

Cautionary Statement Regarding Forward-Looking Statements

This document contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements, as they relate to Medco Health Solutions, Inc. or Express Scripts, Inc., the management of either such company or the transaction, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Medco and Express Scripts undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmacy benefit management and specialty pharmacy industries, and other legal, regulatory and economic developments. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance” and similar expressions to identify these forward-looking statements. Actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including, but not limited to, the possibility that (1) Medco and Express Scripts may be unable to obtain stockholder or regulatory approvals required for the merger or may be required to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals; (2) the length of time necessary to consummate the proposed merger may be longer than anticipated; (3) problems may arise in successfully integrating the businesses of Medco and Express Scripts; (4) the proposed merger may involve unexpected costs; (5) the businesses may suffer as a result of uncertainty surrounding the proposed merger; and (6) the industry may be subject to future risks that are described in SEC reports filed by Medco and Express Scripts.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Medco and Express Scripts described in their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the Securities and Exchange Commission

Additional Information About this Transaction

In connection with the proposed Merger, Express Scripts, Inc. will file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Medco and Express Scripts, and a prospectus of Express Scripts, as well as other relevant documents concerning the proposed Merger. Stockholders are urged to read the registration statement and the proxy statement/prospectus contained therein regarding the Merger when they become available and any other relevant documents as well as any amendments or supplements to those documents, because they will contain important information.

You will be able to obtain a free copy of the proxy statement/prospectus, as well as other filings containing information about Medco and Express Scripts, at the SEC’s Internet site (http://www.sec.gov). You will also be able to obtain these documents, free of charge, in the Investor Relations portion of the Company website at http://www.medcohealth.com, under the heading “Investors” and then under “SEC Filings.” Copies of the proxy statement/prospectus and the SEC filings that will be incorporated by reference in the proxy statement/prospectus

can also be obtained, free of charge, by directing a request to Investor Relations, 100 Parsons Pond Drive, Franklin Lakes, NJ, 07417, 201-269-3400.

Medco and Express Scripts and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Medco in connection with the proposed Merger. Information about the directors and executive officers of Medco and their ownership of Medco common stock is set forth in the proxy statement for the Medco 2011 annual meeting of stockholders, as filed with the SEC on Schedule 14A on April 8, 2011. Information about the directors and executive officers of Express Scripts and their ownership of Express Scripts common stock is set forth in the proxy statement for the Express Scripts’ 2011 annual meeting of stockholders, as filed with the SEC on Schedule 14A on March 21, 2011. Additional information regarding the interests of those persons and other persons who may be deemed participants in the Merger may be obtained by reading the proxy statement/prospectus regarding the proposed Merger when it becomes available. You may obtain free copies of this document as described in the preceding paragraph.

Item 9.01 Financial Statements and Exhibits

     (d) Exhibits.

The following exhibits are being filed herewith:

Exhibit No.	Exhibit
99.1	BetterRxCare.com — Home Page
99.2	BetterRxCare.com — Clients Page
99.3	BetterRxCare.com — Pharmacies Page
99.4	BetterRxCare.com — Consumers Page
99.5	BetterRxCare.com — Investor Presentation
99.6	BetterRxCare.com — Factsheet
99.7	BetterRxCare.com — Merger Photos

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDCO HEALTH SOLUTIONS, INC.
By:	/s/ Thomas M. Moriarty
	Thomas M. Moriarty
	General Counsel, Secretary and President, Global Pharmaceutical Strategies

Date: August 1, 2011

EX-99.1

Exhibit 99.1

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement

Home Clients Pharmacies Consumers Investors Regulatory Filings Press Room Contact Express-Scripts’ CEO, George Paz (right) and Medco’s CEO, David Snow (left) announce the merger of their pharmacy benefit management companies on Thursday morning in St. Louis. The CEOs said the combined company will lead the effort to lower costs of prescription medicines for American families. THIS IS THE COMBINATION THE NATION NEEDS NOW. “The cost and quality of healthcare is a great concern to all Americans; this is the right deal at the right time for the right reasons. Companies like ours have a responsibility to provide the leadership and resources required to drive out waste in healthcare and provide the best care in the world. The merger with Medco will accelerate our efforts to create greater efficiencies in the healthcare system and better protect American families from the rising costs of prescription medicine while improving health outcomes.” — George Paz, Chairman and CEO, Express Scripts CLIENTS AND CONSUMERS WILL BENEFIT FROM THE COMBINATION OF COMPLEMENTARY CAPABILITIES. This transaction will bring together two of healthcare’s most innovative and accomplished organizations. The transaction will unite the companies’ complementary strengths in market coverage, clinical innovation and the behavioral sciences along with operational and technological excellence to meet the new realities dictated by significant industry trends – realities that have our clients demanding that we accelerate value creation. Express Scripts’ successful track record of mergers and acquisitions is based on a philosophy of combining the best processes and brightest people for the benefit of our clients. WE PROTECT AMERICAN FAMILIES FROM THE RISING COSTS OF PRESCRIPTION MEDICINES. EXPRESS SCRIPTS FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This materialmay include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: STANDARD OPERATING FACTORS z Our ability to remain profitable in a very competitive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; z Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry; z Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant

resources in order to comply; z Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; z Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; z A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; z Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses; z The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; z The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; z Changes in industry pricing benchmarks; z Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; z Our failure to execute on, or other issues arising under, certain key client contracts; z The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; TRANSACTION-RELATED FACTORS z Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; z The ability to obtain governmental approvals of the transaction with Medco; z Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; z Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; z Uncertainty as to the long-term value of Express Scripts Holding Company (currently known as Aristotle Holding, Inc.) common shares; z Limitation on the ability of Express Scripts and Express Scripts Holding Company to incur new debt in connection with the transaction; z The expected amount and timing of cost savings and operating synergies; and z Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express Scripts’ most recent reports on Form 10-K and Form 10-Q and the risk factors included in Medco’s most recent reports on Form 10-K and Form 10-Q and other documents of Express Scripts, Express Scripts Holding Company and Medco on file with the Securities and Exchange Commission (“SEC”). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statem ent, whether as a result of new information, future developments or otherwise. ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Express Scripts Holding Company In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Express Scripts Holding Company, Plato Merger Sub Inc. and Express Scripts Merger Sub, Inc. (the “Merger”), Medco, Express Scripts and Express Scripts Holding Company, intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Express Scripts Holding Company, that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, EXPRESS SCRIPTS HOLDING COMPANY AND THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Express Scripts Holding Company or Medco with the SEC, may be obtained free of charge at the SEC’s web site at http://www.sec.gov/. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016 This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. PARTICIPANTS IN THE SOLICITATION Express Scripts, Express Scripts Holding Company and Medco and their respective executive officers and directors may

be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. Information about Express Scripts’ directors and executive officers is available in Express Scripts’ definitive proxy statement, dated March 21, 2011, for its 2011 annual general meeting of stockholders. Information about Medco’s directors and executive officers is available in Medco’s definitive proxy statement, dated April 8, 2011, for its 2011 annual general meeting of stockholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus regarding the Merger that Express Scripts Holding Company, will file with the SEC when it becomes available.

EX-99.2

Exhibit 99.2

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement Home Clients Pharmacies Consumers Investors FOR OUR CLIENTS, THIS IS THE RIGHT COMBINATION AT THE RIGHT TIME. Regulatory Filings As you know, the cost and quality of healthcare is of great concern to all Americans. By combining with Medco, we will be able to accelerate our efforts to promote greater efficiencies in the healthcare system and work with you to better protect Press Room American families from the rising costs of prescription medications while improving care. Contact We are excited about this combination because we believe it will deliver great value for you and your members in a number of ways, including: z Generating greater cost savings for plan sponsors. z Closing gaps in care and achieving greater adherence through our combined behavioral and clinical approaches. z Utilizing our collective expertise to better manage the cost and care associated with specialty medications. We do not anticipate any changes to our existing relationship with you. We remain fully aligned with your objectives and committed to providing you and your members with the highest quality service available in the industry. We value your business and thank you for your continued partnership. Client FAQS z How will the merger benefit clients? z Collectively, we have distinguished ourselves in the areas of clinical, specialty, research, pharmacogenomics, the behavioral sciences, pharmacy technology, account management and overall patient services, and we believe our respective clients and patients will benefit from our complementary capabilities. z The merged company will advance healthcare through innovation and an unwavering alignment with clients. z Will there be any disruption to client service as a result of this announcement? z In the immediate term, nothing will change for our clients. The transaction is expected to close within the next 12 months, at which point, we will have a dedicated integration team to ensure a seamless transition for our clients. z We are committed to continuing our high-level service to you and your patients. z What are your plans for the integration? z While it is too early to discuss the specifics of the integration, Express Scripts has a proven track record of successfully integrating organizations, which is based on our philosophy of combining the best processes and the brightest people for the benefit of our clients. z This merger will be no different – the process will be undertaken in a thoughtful way to best position the future company. z Will Medco and Express Scripts both be participating in next year’s selling season if the deal has yet to complete? z Both companies will continue to operate independently until the transaction is approved and finalized. z Who can I contact if I have further questions about the proposed merger? z If you have further questions, please reach out to your contact on our Sales and Account management team. Click here to view factsheet [pdf] EXPRESS SCRIPTS FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This material may include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: STANDARD OPERATIN G FACTORS z Our ability to remain profitable in a very competitive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; z Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry;

z Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply; z Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; z Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; z A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; z Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses; z The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; z The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; z Changes in industry pricing benchmarks; z Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; z Our failure to execute on, or other issues arising under, certain key client contracts; z The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; TRANSACTION-RELATED FACTORS z Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; z The ability to obtain governmental approvals of the transaction with Medco; z Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; z Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; z Uncertainty as to the long-term value of Express Scripts Holding Company (currently known as Aristotle Holding, Inc.) common shares; z Limitation on the ability of Express Scripts and Express Scripts Holding Company to incur new debt in connection with the transaction; z The expected amount and timing of cost savings and operating synergies; and z Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express Scripts’ most recent reports on Form 10-K and Form 10-Q and the risk factors included in Medco’s most recent reports on Form 10-K and Form 10-Q and other documents of Express Scripts, Express Scripts Holding Company and Medco on file with the Securities and Exchange Commission (“SEC”). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Express Scripts Holding Company In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Express Scripts Holding Company, Plato Merger Sub Inc. and Express Scripts Merger Sub, Inc. (the “Merger”), Medco, Express Scripts and Express Scripts Holding Company, intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Express Scripts Holding Company, that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, EXPRESS SCRIPTS HOLDING COMPANY. AND THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Express Scripts Holding Company or Medco with the SEC, may be obtained free of charge at the SEC’s web site at http://www.sec.gov/. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016 This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

PARTICIPANTS IN THE SOLICITATION Express Scripts, Express Scripts Holding Company and Medco and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. Information about Express Scripts’ directors and executive officers is available in Express Scripts’ definitive proxy statement, dated March 21, 2011, for its 2011 annual general meeting of stockholders. Information about Medco’s directors and executive officers is available in Medco’s definitive proxy statement, dated April 8, 2011, for its 2011 annual general meeting of stockholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus regarding the Merger that Express Scripts Holding Company, will file with the SEC when it becomes available.

EX-99.3

Exhibit 99.3

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement Home Clients Pharmacies Consumers Investors EXPRESS SCRIPTS AND PHARMACIES: A PARTNERSHIP FOR PROGRESS Regulatory Filings Express Scripts is proud of the relationships it has built over the past 25 years with pharmacies of every type. Pharmacies, big and small, are our partners, and we have built business and network relationships that have ensured Press Room safe and effective service for our customers. We look forward to fostering those relationships as we continue our efforts Contact to work to improve America’s healthcare delivery system. z Improving Efficiency: Express Scripts, Medco and other PBMs have played an important role in helping retail pharmacies gain the benefits of modern technology. Reimbursement from insurers used to involve paper forms, carbon copies and long waits for payment. Today, our payment processing systems give pharmacists more time to spend counseling patients instead of filling out forms. z Removing Uncertainty: For smaller pharmacies in particular, finding out whether a prescription was covered could once take weeks, or even months. When a medication wasn’t covered, recouping payment from customers was a difficult process. Our instant adjudication systems remove the uncertainty and risk, a major boon for pharmacies with low operating margins. z Enhancing Prescription Adherence: More than twenty percent of first-time prescriptions in the United States go unfilled, according to a 2010 study from Harvard Medical School. The problem is particularly acute for chronic disease treatments, which are often refillable. Express Scripts’ leadership in applying sophisticated behavioral research to drive better health, yields improvements that benefit both patients and the pharmacies that serve them. z Assisting in the Practice: When pharmacists are limited to the information in their own systems and what patients share about their therapies, costly prescription drug errors can occur. Express Scripts’ system notifies pharmacists of harmful interactions, contraindications and other clinical criteria that assist them in practicing pharmacy. z Promoting 21st Century Pharmacy: Express Scripts and other PBMs partnered with independent and chain pharmacies to create SureScripts, the nation’s largest e-prescribing network. SureScripts connects almost 250,000 prescribers to 91% of the pharmacies in the United States. The use and promotion of e-prescribing saves lives, improves quality and decreases costs for pharmacies. z Strengthening the Profession: Express Scripts employs more than 1,900 pharmacists and pharmacy technicians and has helped hundreds of students complete their pharmacy training. Many of these employees are active in professional societies and associations, working to keep the profession at the front line of improving patient health and strengthening the healthcare system. Click here to view factsheet [pdf] EXPRESS SCRIPTS FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This materialmay include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: STANDARD OPERATING FACTORS z Our ability to remain profitable in a very competit ive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; z Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry; z Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply; z Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; z Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; z A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; z Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses;

z The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; z The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; z Changes in industry pricing benchmarks; z Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; z Our failure to execute on, or other issues arising under, certain key client contracts; z The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; TRANSACTION-RELATED FACTORS z Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; z The ability to obtain governmental approvals of the transaction with Medco; z Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; z Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; z Uncertainty as to the long-term value of Express Scripts Holding Company (currently known as Aristotle Holding, Inc.) common shares; z Limitation on the ability of Express Scripts and Express Scripts Holding Company to incur new debt in connection with the transaction; z The expected amount and timing of cost savings and operating synergies; and z Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express ScriptsI most recent reports on Form 10-K and Form 10-Q and the risk factors included in MedcoIs most recent reports on Form 10-K and Form 10-Q and other documents of Express Scripts, Express Scripts Holding Company and Medco on file with the Securities and Exchange Commission ("SEC"). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Express Scripts Holding Company In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Express Scripts Holding Company, Plato Merger Sub Inc. and Express Scripts Merger Sub, Inc. (the MIergerE), Medco, Express Scripts and Express Scripts Holding Company, intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Express Scripts Holding Company, that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, EXPRESS SCRIPTS HOLDING COMPANY. AND THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Express Scripts Holding Company or Medco with the SEC, may be obtained free of charge at the SECIs web site at http://www.sec.gov/. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016 This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. PARTICIPANTS IN THE SOLICITATION Express Scripts, Express Scripts Holding Company and Medco and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. Information about Express ScriptsI directors and executive officers is available in Express ScriptsI definitive proxy statement, dated March 21, 2011, for its 2011 annual general meeting of stockholders. Information about MedcoIs directors and executive officers is available in MedcoIs definitive proxy statement, dated April 8, 2011, for its 2011 annual general meeting of stockholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus regarding the Merger that Express Scripts Holding Company, will file with the SEC when it becomes available.

EX-99.4

Exhibit 99.4

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement Home            Clients Pharmacies Consumers Investors            Building on a Legacy of Consumer Advocacy Regulatory Filings WE PROTECT AMERICAN FAMILIES FROM THE RISING COSTS OF PRESCRIPTION MEDICINES. THE COMBINATION STRENGTHENS OUR ROLE AS A CONSUMER ADVOCATE. Press Room Contact            Alignment of Interests Since it was founded in 1986, Express Scripts has worked continually to make the use of prescription drugs safer and more affordable for tens of millions of consumers through thousands of employers, government, union and health plans. This will remain a priority for the combined company and we are committed to aligning our interests with those of plan sponsors and you, their members. Reducing Cost and Enhancing Quality of Healthcare The cost and quality of healthcare is a great concern to all Americans. For example, by 2014, spending for specialty medicines for diseases such as cancer, multiple sclerosis and hepatitis is estimated to comprise 40% of U.S. drug spend. By combining both Express Scripts and Medco’s innovative specialty patient care programs, Express Scripts will be well positioned to meet the challenges in this critical area of healthcare. Improving Health Outcomes Patients across the country count on Express Scripts to supply the information and treatment they need to maintain a healthy lifestyle. The pharmaceutical landscape is dynamic and complex and consumer advocacy is required to help them best navigate it. This merger with Medco will accelerate our efforts to create greater efficiencies in the healthcare system and better protect American families from the rising costs of prescription medicine while improving health outcomes. Consumer FAQs: z How will this combination benefit consumers? z Our combined company will accelerate efforts to promote greater efficiencies in the healthcare system and better protect American families from the rising cost of prescription medicine. z At the same time, it will improve care, expand access and further enhance the overall member experience. z Will there be any impact on the continuity of drug availability or drug access? z There will be no disruption to the accessibility or availability of drugs. z We will continue to fulfill the access requirements for our clients and their members. z Will there be any impact on drug pricing? z Our goal is to make sure that patients have access to the medicines they need at the best possible price. This combination will accelerate our ability to meet that goal. z I currently receive mail order prescriptions from Medco; will I now receive them from Express Scripts? z Nothing will change in the immediate term as a result of this announcement. The transaction is expected to close within the next 12 months, at which point we will carefully assess the best way to merge our pharmacy mail technology with minimum disruption to patients. z Who should I contact if I have further questions about the merger and my prescription medications? z Please contact your health insurance provider if you have further questions. Click here to view factsheet [pdf] EXPRESS SCRIPTS FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This materialmay include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are b eyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: STANDARD OPERATING FACTORS

z Our ability to remain profitable in a very competitive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; z Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry; z Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply; z Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; z Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; z A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; z Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses; z The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; z The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; z Changes in industry pricing benchmarks; z Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; z Our failure to execute on, or other issues arising under, certain key client contracts; z The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; TRANSACTION-RELATED FACTORS z Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; z The ability to obtain governmental approvals of the transaction with Medco; z Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; z Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; z Uncertainty as to the long-term value of Express Scripts Holding Company (currently known as Aristotle Holding, Inc.) common shares; z Limitation on the ability of Express Scripts and Express Scripts Holding Company to incur new debt in connection with the transaction; z The expected amount and timing of cost savings and operating synergies; and z Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express Scripts’ most recent reports on Form 10-K and Form 10-Q and the risk factors included in Medco’s most recent reports on Form 10-K and Form 10-Q and other documents of Express Scripts, Express Scripts Holding Company and Medco on file with the Securities and Exchange Commission (“SEC”). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Express Scripts Holding Company In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Express Scripts Holding Company, Plato Merger Sub Inc. and Express Scripts Merger Sub, Inc. (the “Merger”), Medco, Express Scripts and Express Scripts Holding Company, intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Express Scripts Holding Company, that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, EXPRESS SCRIPTS HOLDING COMPANY. AND THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Express Scripts Holding Company or Medco with the SEC, may be obtained free of charge at the SEC’s web site at http://www.sec.gov/. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. PARTICIPANTS IN THE SOLICITATION Express Scripts, Express Scripts Holding Company and Medco and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. Information about Express Scripts’ directors and executive officers is available in Express Scripts’ definitive proxy statement, dated March 21, 2011, for its 2011 annual general meeting of stockholders. Information about Medco’s directors and executive officers is available in Medco’s definitive proxy statement, dated April 8, 2011, for its 2011 annual general meeting of stockholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus regarding the Merger that Express Scripts Holding Company, will file with the SEC when it becomes available.

EX-99.5

Exhibit 99.5

Leading the Effort to Lower Drugs Costs for American Families

Presenters 3 George Paz Express Scripts, Inc. Chairman & Chief Executive Officer 3 David Snow Medco Health Solutions, Inc. Chairman & Chief Executive Officer 3 Jeff Hall Express Scripts, Inc. Executive Vice President & Chief Financial Officer

^© 2011 Express Scripts, Inc — All Rights Reserved.

Agenda 3 Benefits of Merger 3 Transaction Overview & Financial Consideration 3 Q&A ^© 2011 Express Scripts, Inc — All Rights Reserved.

+ A combination the nation needs now: Lowers healthcare costs while improving patient care ^© 2011 Express Scripts, Inc — All Rights Reserved.

Benefits of the Combination 3 Addresses national mandate for more affordable, higher quality healthcare 3 Provides leadership and resources required to drive out waste and improve health outcomes 3 Accelerates efforts to create greater efficiencies in healthcare 3 Builds on our legacy of advancing healthcare through innovation and an unwavering alignment with clients Better positioned for long-term growth opportunities ^© 2011 Express Scripts, Inc — All Rights Reserved.

Clients and Members Will Benefit Generate greater cost savings for patients and plan sponsors Invite collaboration Utilize expertise to better across the healthcare manage the cost and care continuum to drive associated with specialty innovation Well-positioned to drugs drive out waste in healthcare and provide the best care Close gaps in care and Create more efficiency in achieve greater adherence the supply chain through behavioral approach and clinical Accelerates research, strengths development and deployment of trend management tools ^© 2011 Express Scripts, Inc — All Rights Reserved.

The Right Transaction for Medco 3 Enhances Medco’s successful track record of performance 3 22% EPS CAGR since spin-off in 2003 3 Built world-class specialty business 3 Implemented numerous innovations (Therapeutic Resource Centers, DNA Direct, Medco Research Institute)

3 Executed diversification strategy (UBC acquisition, Medco Celesio BV JV, investment in Europa Apotheek Venlo)

3 Unites two PBMs, with similar cultures and missions 3 Provides Medco shareholders a premium for their shares 3 Offers participation in significant long-term growth potential from this transaction ^© 2011 Express Scripts, Inc — All Rights Reserved.

Combining Complementary Expertise Via Consumerology^® and Clinical Innovation Specialist Behavioral Care Personalized Safety & Health Proven Tools Pharmacist Insights Coordination Medicine Outcomes Model 3 More than 3 Choice 3 Clinical 3 TRCs driving 3 Pharma- 3 Medco Research money architecture and data increased cogenomics Institute 3 One size 3 Framed integration adherence and 3 DNA Direct^® 3 UBC^® does not fit all messaging 3 Specialty benefit compliance (REMS/ 3 Key 3 Predictive services Safety/ psychological modeling CER) forces Drive Out Waste and Improve Health Benefits of Combination 3 Increased therapy adherence 3 Lower costs 3 Better outcomes Note: TRC = Therapeutic Resource Centers; REMS = Risk Evaluation and Mitigation Strategies; CER = Comparative Effectiveness Research. ^© 2011 Express Scripts, Inc — All Rights Reserved.

Building Shareholder Value Through Alignment + Complements Core Enhances Specialty Adds Additional Mail Significant Synergy Diversifies Business Competencies Pharmacy Platform Order Capabilities Potential ^© 2011 Express Scripts, Inc — All Rights Reserved.

Track Record of Execution and Innovation Commitment to Building Shareholder Value $60.00$3,000 ESRX stock price has increased over 25,000% NextRx $48.00$2,400 since IPO in 1992 $4,675m $251m (EBITDA $36.00 $1,800 share price) in millions) (Indexed $24.00 $2,408 $1,200 $1,268m $1,693 $333m $1,378 $12.00DIVERSIFIED^®$466m $1,186 $600 $715m $915 $460m$727 $503 $563 $454 $278 $315 $239 $59 $116 $0.00 $0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 EBITDA Express Scripts S&P 500 Note: Represents Adjusted EBITDA from continuing operations which is reconciled in tables in our earnings releases; adjusted to exclude non-recurring items. History of building shareholder value through successful acquisition strategy ^© 2011 Express Scripts, Inc — All Rights Reserved.

+ Creating significant value: Successful track record of creating shareholder value through organic growth and strategic combinations ^© 2011 Express Scripts, Inc — All Rights Reserved.

Transaction Overview 3 $28.80 cash and 0.81 of a share of Express Scripts stock (fixed exchange ratio); total consideration of $29.1 billion Price 3 Total value of $71.36 per Medco share based on Express Scripts’ closing stock price on July 20, 2011 328% premium to Medco shareholders based on Medco’s closing Premium            stock price on July 20, 2011 3 Express Scripts shareholders to own approximately 59% and Ownership Medco shareholders to own approximately 41% of the combined company 3 First half of 2012, subject to regulatory approvals Anticipated Closing ^© 2011 Express Scripts, Inc — All Rights Reserved.

Significant Financial Benefits 3 Slightly accretive in first full year; moderately accretive post integration 3 $1 billion of synergies when fully integrated 3 Maintains Express Scripts’ Strong Financial Profile 3 Cash Flow: $4 billion+ of annual free cash flow post integration 3 Capex: Disciplined capex deployment 3 Credit Rating: Commitment to maintaining investment grade credit rating 3 Earnings growth: Maintain industry-leading growth rate ^© 2011 Express Scripts, Inc — All Rights Reserved.

Track Record of Execution and Innovation Commitment to De-Leveraging 5.0x $3,000 4.5x 4.0x $2,400 $460m 3.5x            DIVERSIFIED^® NextRx 3.1x $715m EBITDA) (Adjusted$4,675m 3.0x $1,800 2.7x $1,268m $251m 2.5x EBITDA2.3x Adjusted 2.1x 2.0x $2,408 $1,200 1.7x in $466m millions) 1.5x 1.4x 1.3x 1.5x 1.2x $333m $1,693 1.1x 1.0x (Total debt / 0.9x $1,378 1.0x 0.8x $1,186 $600 $915 $727 0.5x $563 $454 $503 $278 $315 $239 $59 $116 – $0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Adjusted EBITDA Total debt / Adjusted EBITDA Note: Represents Adjusted EBITDA from continuing operations which is reconciled in tables in our earnings releases; adjusted to exclude non-recurring items. Proven success integrating strategic acquisitions and reducing leverage rapidly ^© 2011 Express Scripts, Inc — All Rights Reserved.

Regulatory Approval 3 Significant benefits in the public interest • Lowers costs and improves outcomes for clients and members • Improves the overall quality of healthcare by ensuring proper compliance, avoiding adverse reactions and providing customers the feedback to live healthier lives • Facilitates cooperation across healthcare continuum to drive innovation 3 Competition is vibrant and will only increase • Significant number of diverse competitors • Diverging PBM business models continue to emerge ^© 2011 Express Scripts, Inc — All Rights Reserved.

Roadmap to Completion 3 Complete required filings 3 Special meetings for Express Scripts and Medco shareholder approval 3 Receive regulatory approvals • Hart-Scott-Rodino 3 Transaction expected to be completed in the first half of 2012 ^© 2011 Express Scripts, Inc — All Rights Reserved.

FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This material may include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: STANDARD OPERATING FACTORS • Our ability to remain profitable in a very competitive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; • Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry; • Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply; • Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; • Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; • A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; • Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses; • The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; • The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; • Changes in industry pricing benchmarks; • Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; • Our failure to execute on, or other issues arising under, certain key client contracts; • The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; ^© 2011 Express Scripts, Inc — All Rights Reserved.

FORWARD LOOKING STATEMENTS (Continued) TRANSACTION-RELATED FACTORS • Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; • The ability to obtain governmental approvals of the transaction with Medco; • Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; • Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; • Uncertainty as to the long-term value of Aristotle Holding, Inc. common shares; • Limitation on the ability of Express Scripts and Aristotle Holding, Inc. to incur new debt in connection with the transaction; • The expected amount and timing of cost savings and operating synergies; and • Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express Scripts’ most recent reports on Form 10-K and Form 10-Q and the risk factors included in Medco’s most recent reports on Form 10-K and Form 10-Q and other documents of Express Scripts, Aristotle Holding, Inc. and Medco on file with the Securities and Exchange Commission (“SEC”). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. ^© 2011 Express Scripts, Inc — All Rights Reserved.

ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Aristotle Holding, Inc. In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Aristotle Holding, Inc., Plato Merger Sub Inc. and Aristotle Merger Sub, Inc. (the “Merger”), Medco, Express Scripts and Aristotle Holding, Inc., intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Aristotle Holding, Inc., that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, ARISTOTLE HOLDING, INC. THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Aristotle Holding, Inc. or Medco with the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016 This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. PARTICIPANTS IN THE SOLICITATION Express Scripts, Aristotle Holding, Inc. and Medco and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. Information about Express Scripts’ directors and executive officers is available in Express Scripts’ definitive proxy statement, dated March 21, 2011, for its 2011 annual general meeting of stockholders. Information about Medco’s directors and executive officers is available in Medco’s definitive proxy statement, dated April 8, 2011, for its 2011 annual general meeting of stockholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and joint proxy statement/prospectus regarding the Merger that Aristotle Holding, Inc., will file with the SEC when it becomes available. ^© 2011 Express Scripts, Inc — All Rights Reserved.

Leading the Effort to Lower Drugs Costs for American Families

EX-99.6

Exhibit 99.6

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement IMPROVING HEALTH AND LOWERING THE COST OF MEDICINES FOR AMERICAN FAMILIES Companies Headquarters St. Louis, MO Franklin Lakes, NJ Ticker NASDAQ: ESRX NYSE: MHS Description Express Scripts makes the use of prescription Medco is pioneering the world’s most drugs safer and more affordable for tens of advanced pharmacy^®, and its clinical millions of consumers through thousands of research and innovations are part of employers, government, union and health Medco making medicine smarter for plans. Founded in 1986 and never owned by more than 65 million members. Medco a drug manufacturer, Express Scripts aligns employees worldwide are dedicated to its interests with those of plan sponsors and improving patient health and reducing their members. Express Scripts is leading the costs for a wide range of public and private way toward creating better health and value sector clients. Medco ranks 34th on the for patients through Consumerology^®, the 2011 Fortune 500 list and is named among advanced application of the behavioral the world’s most innovative, most admired sciences to healthcare. and most trustworthy companies. www.Express-Scripts.com www.MedcoHealth.com Employees 13,170 24,625 (2010) 2010 Revenue $44.9 billion $66.0 billion Strategic ?? Generate greater cost savings for patients and plan sponsors Rationale ?? Create more efficiency in the supply chain ?? Close gaps in care and achieve greater adherence by combining leading clinical capabilities with the proven application of the behavioral sciences ?? Utilize our collective expertise to better manage the cost and care associated with specialty medications ?? Optimize our ability to respond to an increasingly complex Medicare and Medicaid environment ?? Enhance mail pharmacy technology to optimize patient care and satisfaction ?? Accelerate the research, development and deployment of trend management solutions to address inefficiencies in the marketplace ?? Advance our efforts against fraud, waste and abuse ?? Attract other leading healthcare entities to collaborate on next-generation solutions

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement IMPROVING HEALTH AND LOWERING THE COST OF MEDICINES FOR AMERICAN FAMILIES Industry ?? Addresses national mandate for more affordable, higher quality healthcare Leadership ?? Provides leadership required to drive out waste and improve health outcomes ?? Accelerates efforts to create greater efficiencies in healthcare ?? Will advance healthcare through innovation and an unwavering alignment with clients Financial ?? Slightly accretive to EPS in first full year; moderately accretive post integration Benefits ?? $1 billion of synergies when fully integrated ?? Maintains Express strong financial profile through: Scripts’ o Cash Flow: $4 billion+ of annual free cash flow post integration o Capex: Disciplined capex deployment o Credit Rating: Commitment to maintaining investment grade credit rating o Earnings growth: Maintain industry-leading growth rate Transaction ?? Consideration to be received by Medco shareholders is valued at $71.36 per share, or Terms $29.1 billion in the aggregate ?? Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts for each Medco share they own ?? Upon closing of the transaction, Express Scripts shareholders are expected to own approximately 59 percent of the combined company and Medco shareholders are expected to own 41 percent Approvals The merger is subject to regulatory shareholder approvals and other customary closing conditions. WHERE TO FIND ADDITIONAL INFORMATION Information is available at www.BetterRxCare.com or www.Express-Scripts.com. FORWARD-LOOKING STATEMENTS EXPRESS SCRIPTS FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This material may include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,”“intend,” “plan,” “believe,” “project,” or forward-looking nature may be used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond our control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following:

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement IMPROVING HEALTH AND LOWERING THE COST OF MEDICINES FOR AMERICAN FAMILIES STANDARD OPERATING FACTORS Our ability to remain profitable in a very competitive marketplace is dependent upon our ability to attract and retain clients while maintaining our margins, to differentiate our products and services from others in the marketplace, and to develop and cross sell new products and services to our existing clients; Our failure to anticipate and appropriately adapt to changes in the rapidly changing health care industry; Changes in applicable laws or regulations, or their interpretation or enforcement, or the enactment of new laws or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply; Changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices; Changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D; A failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors; Our failure to effectively execute on strategic transactions, or to integrate or achieve anticipated benefits from any acquired businesses; The termination, or an unfavorable modification, of our relationship with one or more key pharmacy providers, or significant changes within the pharmacy provider marketplace; The termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers; Changes in industry pricing benchmarks; Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings; Our failure to execute on, or other issues arising under, certain key client contracts; The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness; our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives; TRANSACTION-RELATED FACTORS Uncertainty as to whether Express Scripts, Inc. (Express Scripts) will be able to consummate the transaction with Medco Health Solutions, Inc. (Medco) on the terms set forth in the merger agreement; The ability to obtain governmental approvals of the transaction with Medco; Uncertainty as to the actual value of total consideration to be paid in the transaction with Medco; Failure to realize the anticipated benefits of the transaction, including as a result of a delay in completing the transaction or a delay or difficulty in integrating the businesses of Express Scripts and Medco; Uncertainty as to the long-term value of Express Scripts Holding Company (currently known as Aristotle Holding, Inc.) common shares; Limitation on the ability of Express Scripts and Express Scripts Holding Company to incur new debt in connection with the transaction; The expected amount and timing of cost savings and operating synergies; and            Failure to receive the approval of the stockholders of either Express Scripts or Medco for the transaction.

Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement IMPROVING HEALTH AND LOWERING THE COST OF MEDICINES FOR AMERICAN FAMILIES The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in Express Scripts’ -K and Form most 10-Q and therecent risk factors included in Medco’s most -K and Form 10-Q recent and other documents of reports on Express Scripts,Form 10 Express Scripts Holding Company and Medco on file with the Securities and Exchange Commission (“SEC”). Any forward-looking statements made in this material are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication is not a solicitation of a proxy from any stockholder of Express Scripts, Medco or Express Scripts Holding Company In connection with the Agreement and Plan of Merger among Medco, Express Scripts, Express Scripts Holding Company, Plato Merger Sub Inc. and Express Scripts Merger Sub, Medco, Express Scripts and Express Scripts Holding Company, intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Express Scripts Holding Company, that will contain a joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDCO, EXPRESS SCRIPTS, EXPRESS SCRIPTS HOLDING COMPANY. AND THE MERGER. The Form S-4, including the joint proxy statement/prospectus, and other relevant materials (when they become available), and any other documents filed by Express Scripts, Express Scripts Holding Company or Medco with the SEC, may be obtained free of charge at the SEC’s web www.sec.gov site . In addition,at investors and security holders may obtain free copies of the documents filed with the SEC by directing a written request to: Mackenzie Partners, Inc. 105 Madison Avenue New York, New York 10016 This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. PARTICIPANTS IN THE SOLICITATION Express Scripts, Express Scripts Holding Company and Medco and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of either Express Scripts and Medco in connection with the Merger. executive officers is available in Express Scripts’ annual general meeting of stockholders. Information about Medco’s directors in Medco’s definitive proxy statement, dated April Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus regarding the Merger that Express Scripts Holding Company, will file with the SEC when it becomes available.

EX-99.7

Exhibit 99.7

Express-Scripts’ CEO, George Paz (right) and Medco’s CEO, David Snow (left) announce the merger of their pharmacy benefit management companies on Thursday morning in St. Louis. The CEOs said the combined company will lead the effort to lower costs of prescription medicines for American families. Click here for Hi-Resolution Photo (JPG)

Express-Scripts’ CEO, George Paz (right) and Medco’s CEO, David Snow (left) announce the merger of their pharmacy benefit management companies on Thursday morning in St. Louis. The CEOs said the combined company will lead the effort to lower costs of prescription medicines for American families. Click here for Hi-Resolution Photo (JPG)